دورية أكاديمية
أعرض في EDS

SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023.

التفاصيل البيبلوغرافية
العنوان: SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023.
المؤلفون: Tannis A, Englund JA, Perez A, Harker EJ, Staat MA, Schlaudecker EP, Halasa NB, Stewart LS, Williams JV, Michaels MG, Selvarangan R, Schuster JE, Sahni LC, Boom JA, Weinberg GA, Szilagyi PG, Clopper BR, Zhou Y, McMorrow ML, Klein EJ, Moline HL
المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Dec 01; Vol. 72 (48), pp. 1300-1306. Date of Electronic Publication: 2023 Dec 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: Atlanta, GA : U.S. Centers for Disease Control
Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control.
مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/prevention & control , Vaccines*, Child ; Infant ; United States/epidemiology ; Humans ; Child, Preschool ; COVID-19 Vaccines ; SARS-CoV-2/genetics ; Prospective Studies ; Vaccine Efficacy ; Hospitalization ; RNA, Messenger
مستخلص: SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19-associated emergency department (ED) visits and hospitalization in this population are limited. Data from the New Vaccine Surveillance Network, a prospective population-based surveillance system, were used to estimate vaccine effectiveness using a test-negative, case-control design and describe the epidemiology of SARS-CoV-2 in infants and children aged 6 months-4 years during July 1, 2022-September 30, 2023. Among 7,434 children included, 5% received a positive SARS-CoV-2 test result, and 95% received a negative test result; 86% were unvaccinated, 4% had received 1 dose of any vaccine product, and 10% had received ≥2 doses. When compared with receipt of no vaccines among children, receipt of ≥2 COVID-19 mRNA vaccine doses was 40% effective (95% CI = 8%-60%) in preventing ED visits and hospitalization. These findings support existing recommendations for COVID-19 vaccination of young children to reduce COVID-19-associated ED visits and hospitalization.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Janet A. Englund reports institutional support from AstraZeneca, GSK, Pfizer-BioNTech, and Merck & Co. and consulting fees from Abbvie, AstraZeneca, Ark Biopharma, Meissa Vaccines, Moderna, Sanofi Pasteur, Shinogi, GSK, and Pfizer-BioNTech. John V. Williams reports institutional support from the National Institutes of Health (NIH) and compensation for service on Quidel’s Scientific Advisory Board through 2022 and on GSK’s Independent Data Monitoring Committee. Marian G. Michaels reports support from the National Institute of Allergy and Infectious Diseases, NIH, and Merck & Co.; receipt of lecture honoraria from the Transplant Alliance; support for meeting attendance from NIH, the Infectious Diseases Society of America, the Transplant Alliance, the American Society of Transplantation, and the International Transplant Nurses Association; participation on a National Institute of Allergy and Infectious Diseases Data Safety Monitoring Board; and services as Chair of the Infectious Diseases Committee of the International Pediatric Transplant Association. Geoffrey A. Weinberg reports institutional support from the New York State Department of Health AIDS Institute and honoraria from Merck & Co. for writing and editing textbook chapters in the Merck & Co. Manual. Natasha B. Halasa reports grants from Sanofi, Quidel, and Merck & Co. Elizabeth P. Schlaudecker reports institutional support from NIH and Pfizer-BioNTech, support for attending a Pediatric Infectious Diseases Society meeting, uncompensated service on NIH Data Safety Monitoring Board, honorarium for service on Sanofi Pasteur advisory board, uncompensated membership in the World Society of Pediatric Infectious Diseases, and uncompensated service as committee chair for the Pediatric Infectious Diseases Society. Mary Allen Staat reports institutional support from NIH, Merck & Co., Cepheid, and Pfizer-BioNTech and receipt of royalties from UpToDate. Peter G. Szilagyi reports a grant to the University of Rochester (subcontract to University of California at Los Angeles) No other potential conflicts of interest were disclosed.
References: MMWR Morb Mortal Wkly Rep. 2022 Jul 01;71(26):859-868. (PMID: 35771731)
MMWR Morb Mortal Wkly Rep. 2023 Feb 17;72(7):177-182. (PMID: 36795625)
Front Public Health. 2021 Nov 23;9:770985. (PMID: 34888288)
MMWR Morb Mortal Wkly Rep. 2023 Aug 18;72(33):886-892. (PMID: 37590187)
Lancet Reg Health Am. 2022 Aug;12:100297. (PMID: 35756977)
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1766-1772. (PMID: 34968374)
JAMA Netw Open. 2022 Feb 1;5(2):e2143151. (PMID: 35133437)
MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):606-608. (PMID: 35482574)
معلومات مُعتمدة: U01 IP001150 United States IP NCIRD CDC HHS; U01 IP001152 United States IP NCIRD CDC HHS; U01 IP001158 United States IP NCIRD CDC HHS
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Vaccines)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20231130 Date Completed: 20231204 Latest Revision: 20240327
رمز التحديث: 20240327
مُعرف محوري في PubMed: PMC10718202
DOI: 10.15585/mmwr.mm7248a2
PMID: 38032834
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-861X
DOI:10.15585/mmwr.mm7248a2